

## Keyword index to Volume 85

- Accelerated chemotherapy 1444  
 Acquired resistance 1064  
 ADCC 463  
 Adenocarcinomas 1023, 1153, 1371, 1781  
 Adenomatous polyposis coli 69, 98  
 Adjuvant chemotherapy 827, 1251  
 Adjuvant therapy 1437  
 Advanced breast cancer 141  
 Advanced gastrointestinal cancer 1265  
 Aetiology 1667  
 Ageing 930  
 Aggressive fibromatosis 98  
 AIDS 1298  
 Alcohol 46, 341, 678  
 Alcohol intake 1700  
 ALIMTA 649  
 Allelic imbalance 1201  
 Alphafetoprotein 1119  
 Aminolevulinic acid 279, 727  
 Aminolevulinic acid derivatives 279  
 Aminolevulinic acid hexylester 727  
 5-Aminolevulinic acid 1572, 1794  
 5-Aminolevulinic acid esters 1572, 1794  
 Aminopeptidase N 924  
 Amsacrine 747  
 Androgen receptors 36, 1928  
 Androgen regulated transcripts 393  
 Angiogenesis 266, 439, 473, 863, 881, 1396, 2010  
 Angiogenesis inhibition 1540  
 Angiotensin 1396  
 Angiotensin II 1640  
 Anthracycline-containing regimen 141  
 Anthracycline/taxane resistance 798  
 Antiangiogenic therapy 584  
 Anti-apoptotic genes 405  
 Anti-cancer drugs 242  
 Antidotal activity 1964  
 Antimicrotubule agents 735  
 Antineoplastic drugs and medications 1400, 1611  
 Anti-p53 antibodies 1883  
 Antisense 1753  
 Anti-tumour activity 741  
 Apoptosis 115, 273, 279, 303, 453, 584, 764, 898, 902, 1047, 1403, 1522, 1564, 1764, 1771, 1781, 1801, 1914, 1964, 2004, 2017  
 AQ4N + cisplatin 625  
 Archival smears 398  
 Arimidex 317  
 Aromatase inhibitors 317  
 Asparagine synthetase 930  
 Assam 661  
 Asthma 1317  
 ATP 1987  
 Attenuated adenomatous polyposis coli 523  
 Avascular necrosis 1624  
 Axillary surgery 668  
 5-Aza-2'-deoxycytidine 1351  
 Basal cells 422  
 Basal cell carcinomas 683, 1883  
 Basic fibroblast growth factor 1706  
 BAX 1359  
 Bax 1557  
 BCL-2 1359  
 Bcl-2 115, 273, 1557, 1564, 1764, 1781  
 Bcl-2 family 1801  
 bcl-2 phosphorylation 1403  
 Bcl-X 1557  
 Benign prostatic hyperplasia 576  
 Betel nut chewing 658, 661  
 BH3 115  
 Biochemotherapy 1871  
 Biomarkers 1952  
 Bioreductive drugs 1137  
 Birthweight 428  
 Bispecific antibodies 152  
 Bladder cancers 568, 1137, 1412, 1515, 1887  
 Bladder neoplasms 552, 977  
 Blood flow 1640, 1655  
 Bloom's syndrome gene product 261  
 Body height 959  
 Body mass 1680  
 Body mass index 372  
 Body surface area estimation 23  
 Body weight 346  
 Body weight/body mass index 984  
 Bone resorption 78  
 Book reviews 1609, 1810, 1811  
 BQ123 1759  
 Brain tumours 285, 1396  
 BRCA1 538  
 BRCA1 36, 845, 850, 1201, 1675  
 BRCA1 gene 1347  
 BRCA2 36, 850, 1201, 1675  
 Breast cancer 1, 69, 78, 85, 171, 141, 225, 317, 372, 422, 428, 490, 538, 618, 637, 668, 798, 859, 869, 917, 959, 962, 1014, 1102, 1157, 1240, 1280, 1289, 1340, 1522, 1675, 1680, 1731, 1764 1878, 1914, 1958, 2017  
 Breast cancer cells 909  
 Breast cancer cell lines 902  
 Breast cancer prevention 1838  
 Breast cancer risks 36  
 Breast cancer therapy 147  
 Breast conservation therapy 668  
 Breast neoplasms 362, 1347  
 Breastfeeding 1685  
 Bromocriptine 1611  
 C225 584  
 c-KIT/SCF 405  
 Cachexia 297  
 Calman-Hine report 166  
 Camptothecin resistance 1077  
 Canada 1335  
 Cancer chemoprevention 618  
 Cancer chemotherapy 1219  
 Cancer gene therapy 1592  
 Cancer genetics services 166  
 Cancer genomics 1492  
 Cancer immunotherapy 1527  
 Cancer immunotherapy, human 1722  
 Cancer incidence 1332  
 Cancer patients 641  
 Cancer registry 367, 1251  
 Cancer screening 1332  
 Cancer vaccine 713  
 Cancer-testis antigens 713  
 Carbonyl reductase 1032  
 Carboxymethylbenzylamide dextran derivative 917  
 Carcinoembryonic antigens 1787  
 Carcinogenesis 1922  
 Carcinomas *in situ* 213  
 Carotenoids 977  
 Case-control studies 337, 341, 398, 683, 966, 991, 1326, 1667  
 Caspase 3 1522  
 Catechol oestrogens 859  
 Catechol-*O*-methyltransferase 859  
 $\beta$ -Catenin 64, 98  
 $\gamma$ -Catenin 64  
 Cathepsin S 1193  
 Caucasians 171  
 CCR1 891  
 CCRF-CEM 1400  
 CD4+ T cell clones 1527  
 CD44(var) 924  
 CDC25A 412  
 CDC25B 412  
 CDDP-based chemotherapy 1064  
 CDHP 939  
 CDK4 genes 836  
 CDKN2A 527  
 CDKN2A genes 836  
 CDKN2A gene 1383  
 cDNA 1351  
 cDNA array 538  
 Cell cultures 285  
 Cell cycles 1771  
 Cell cycle arrest 898  
 Cell growth 1978  
 Cell lines 1014, 1492  
 Cell mediated immunity 473  
 Cell proliferation 1771  
 Cell scattering 1412  
 Cervical cancer 93, 398, 791, 966, 1153, 1675  
 CHART 1113  
 Chemokines 891  
 Chemopotentiation 625  
 Chemosensitivity 1425  
 Chemotherapy 649, 808, 816, 1099, 1240, 1444, 1456, 1646, 1850  
 Chemotherapy steroids 1624  
 Child development 1611  
 Childhood cancer 337, 350, 1680, 1685  
 Chk2 293  
*CHK2* mutations 209  
 Chlorambucil 764  
 Chlorpromazine 1998  
 chLym-1 463  
 Chondrosarcomas 176  
 Chromosomal aberrations 1900  
 Chromosomal radiosensitivity 1157  
 Chromosome 10p15 1510  
 Chromosome 11 531, 1894  
 Chromosome 17 705, 1894  
 Chromosome aberrations 293  
 Chromosome instability 1887  
 Circulating tumour cells 431  
 Cisplatin 9, 823, 1124, 1206, 1456  
 Cleavable complex 1585  
 Cleavase fragment length polymorphism 845  
 Clinical features 538  
 Clinical resistance 509  
 Clinical trials 1432, 1467

- Clonal evolution 182  
 Clonogenic assays 1585  
 CMF 1106  
 CNS toxicity 1233  
 Co-activators 1928  
 Co-localisation 909  
 Cohort studies 346, 362  
 Colchicine 1998  
 Collagenase 383  
 Colon cancer 772, 1251, 1437, 1572  
 Colon neoplasms 1047  
 Colonoscopy 972  
 Colorectal cancer 504, 523, 641, 692, 787, 827, 972, 1037, 1258, 1486, 1695, 1759, 1771, 1937  
 Colorectal liver metastases 1640, 1759  
 Colorectal neoplasms 346, 357  
 Colorectal tumours 764, 1492  
 Comparative genomic hybridization 213, 422, 697, 1492  
 Competing risks 1113  
 Computer touchscreens 1842  
 COMT 859  
 Consanguinity 1675  
 Consultations 1273  
 Continuous hyperfractionated accelerated radiotherapy 1113  
 Contralateral breast cancer 850  
 CpG-methylation 1168  
 Cremophor EL 1124, 1472  
 CTL epitope peptides 1722  
<sup>62</sup>Cu-PTSM 1640  
 Cyclin-dependent kinase inhibitors 1515  
 Cyclo-oxygenase-2 1023  
 Cyclophosphamide 798  
 Cytochrome P450 242  
 Cytoreduction 1824  
 Cytosols 85
- Dacarbazine 1467  
 DC101 584  
 DCC 199  
 Death associated protein kinase family 1801  
 Decorin 228  
 Deletion mutations 176  
 Denaturing gradient gel electrophoresis 235, 523  
 Dermatomyositis 41  
 Dexamethasone 1099  
 Diagnosis 225, 656  
 Diarylsulfonylureas 1400  
 Diet 341  
 Dietary cholesterol 357  
 Differential displays 1162  
 Differentially expressed genes 393  
 Differentiated thyroid cancer 875  
 Differentiation 590, 1944, 2004  
 Diltiazem 1577  
 Dimethylbenz[*a*]anthracene 428
- Dlk/ZIP kinase 1801  
 DNA damage 898  
 DNA methylation 1887  
 DNA microarrays 107  
 DNA ploidy 182  
 Docetaxel 242, 1247  
 Dorsal root ganglia 1219  
 Down-regulation 220  
 Doxorubicin 1964, 1987  
 Drug combinations 1077  
 Drug resistance 735, 902, 1175, 1425  
 Drug targeting 747  
 Ductal carcinoma 225, 422  
 dUTP 446  
 dUTPase 446  
 Dysplastic nevi 1304
- Early detection 803  
 Early onset 859  
 EBAG9/RCAS1 1731  
 E-cadherin 1958  
 Efficacy 1326  
 EGFRvIII 1211  
 Eggs 357  
 Egypt 1037  
 ELISA 1193  
 ELISPOT 1738  
 Emetogenic chemotherapy 1099  
 EMT 1412  
 Endometrial cancer 333, 546  
 Endoscopy 972  
 Endothelial cells 584  
 Endothelin-1 1759  
 Enzyme-linked immunosorbent assay 1193  
 EO9 1137  
 EORTC QLQ-C30 1265  
 Epidemiology 962  
 Epidermal growth factor 303, 84  
 Epidermal growth factor receptors 1600  
 Epidermal growth factor receptor antagonists 1600  
 Epidermal growth factor receptor ligands 1412  
 Epirubicin 1106, 1456  
 Epithelial ovarian cancer 1032  
 Epitopes 875  
 Epstein-Barr virus 350, 997  
 ErbB2 705, 1787  
 ET<sub>A</sub> antagonists 1759  
 ET<sub>B</sub> antagonists 1759  
 Ethnicity 350  
 Etoposides 747  
 EURO CARE 787  
 Ewing's tumour 1646  
 Excess risk 362  
 Exercise 962  
 Exostoses 2 176  
 Expression 1162, 1211  
 Extracellular matrix 1968  
 Extracellular signal-regulated protein kinase-2 1403  
 Extraintestinal mucosa-associated lymphoid tissue lymphoma 1462
- Extravasation 1387
- Failure-specific prognostic factors 1113  
 Falkland Islands 1332  
 False negative cytology 398  
 Familial colorectal cancer 523  
 Familial melanoma 836  
 Familial papillary thyroid carcinoma 1831  
 Family history 674  
 Fas-L 1185  
 Fats 357  
 FcγR 463  
 Females 341  
 Fertility patterns 362  
 Fibroblasts 293  
 Fibroblast growth factor-8 576  
 Fine needle aspiration 1102  
 FISH 1201  
 Flexible modelling 795  
 Fluorescein-colchicine 1998  
 Fluorescence 1572  
 Fluorescence *in situ* hybridization 697, 1201  
 Fluoropyrimidine 439  
 5-Fluorouracil 798, 1258, 1937  
 Focal adhesion kinases 228  
 Folate 977  
 Follicular lymphomas 29  
 Follow-up studies 997  
 Founders 527  
 Fractionated administration 9  
 Fragile histidine triad genes 247  
 France 1664  
 Fusion transcripts 1535
- α-GalCer 741  
 Gallbladder cancer 1922  
 GalNAc glycoproteins 1014  
 Gangliosides 285  
 G<sub>1</sub>-arrest 293  
 Gastric adenoma 1147  
 Gastric cancer 199, 1147, 1317, 1322, 1585  
 Gastrointestinal cancer 1265  
 Gastro-oesophageal reflux 1317  
 Genes 1211  
 Gene amplification and expression 518  
 Gene clones 1162  
 Gene expression 107, 266, 1206, 1372  
 Gene mutations 64  
 Gene overexpression in cancer 190  
 Gene therapy 1432  
 Genetics 1499  
 Genetic analysis 687  
 Genetic counselling 166  
 Genetic polymorphism 859  
 Genistein 618  
 Germ cell tumours 823, 1119  
 Germ line mutations 523, 836  
 Glioblastoma 518  
 Gliomas 55, 1185, 1396
- Glomerular filtration rates 325  
 Glucocorticoids 683, 1611  
 GM-CSF 152, 1444  
 Good practices 1251  
 gp 100/pmel17 1738  
 G<sub>2</sub>-phase 1157  
 G-protein expression 758  
 Granisetron 1099  
 Granulocyte-macrophage colony-stimulating factor 1467  
 Growth hormone antagonists 428  
 Growth inhibition 453  
 Growth kinetics 490  
 Gynaecological oncologists 1824
- Haemangioma 362  
 Haematolymphoproliferative disorders 997  
*Haemophilus influenzae* type b 337  
 Head and neck cancer 630, 1055  
 Head and neck squamous cell carcinoma 649  
 Health service organisation 166  
 Health services accessibility 497  
 Height 1680  
*Helicobacter pylori* 1322  
*Helix pomatia* lectin 1014  
 Helper T cells 1738  
 Heparan sulfate 1094  
 Hepatocarcinogenesis 697  
 Hepatocellular carcinoma 228, 697, 1162, 1850  
 HER2 152  
 HER-2/neu 1764  
 HER-2/neu peptide 1527  
 Hereditary breast cancer 209, 845  
 Hereditary multiple exostoses 176  
 Hereditary non-polyposis colorectal cancer 1486  
 Herpesvirus 8, human 379  
 Heterogeneity 182  
 High throughput screening 1206  
 High-dose chemotherapy 484, 1240  
 High-dose oestrogens 147  
 Histology 1347  
 HIV 1298  
 hMLH1 1147  
 hMSH2 1147  
 Hodgkin's disease 350  
 Homing 1387  
 Hormone replacement therapy 674  
 HPA 1014  
 HPMA copolymer 1070  
 HPV-infection 1153  
 hTERT 752  
 hTR 1510  
 hTRF1 752  
 Humans 171, 1372, 1700  
 Human herpesvirus 8 1298  
 Human papillomavirus 966, 1551  
 Humoral immunity 473

- Hyaluronan receptors 600  
 Hyaluronan synthase 600  
 Hypermethylated in cancer gene-1 1878  
 Hypermethylation 69, 930, 1878  
 Hypersensitivity pneumonitis 1247  
 Hypomethylation 563  
 Hypoxia 891, 1577  
 Hypoxia inducible factors 881  
  
 I1307K APC mutation 1368  
 IgG uptake 1968  
 IgGκ Fab 875  
 Immune evasion 1047  
 Immunocytochemistry staining 1713  
 Immunohistochemistry 576, 1193, 1731, 1922, 1937  
 Immunoluminescence 924  
 Immunophototherapy 1787  
 Immunosuppression 997  
 Immunosuppressive therapy 683  
 Immunotherapy 152, 713  
*In situ* hybridization 383, 869, 1510  
 Incidence 1322, 1335  
 Information and support requests 641  
 Inherited predisposition to cancer 1368  
 Initial therapies 29  
 Insulin 346  
 Insulin-like growth factor binding protein-3 74, 1695  
 Insulin-like growth factor system 147, 1838  
 Insulin-like growth factor-1 74, 428, 991, 1695  
 Insulin-like growth factor-1R inhibitors 2017  
 Insulin-like growth factor-2 1695  
 Intercellular adhesion molecule-1 924, 1351  
 Interferon 29  
 Interferon- $\alpha$  1130  
 Interferon- $\alpha$  sensitivity 107  
 Interferon- $\gamma$  741  
 Interleukin-1 receptor antagonists 1600  
 Interleukin-2 1130  
 Interleukin-6 518  
 Inter-observer variability 1634  
 Interstitial fluid pressure 1968  
 Intraperitoneal topotecan 1627  
 Intrauterine exposures 959  
 Intravital microscopy 431  
 Invasion 122, 869, 1600  
 Ionizing radiation 293, 362  
 Irinotecan 9  
 Irradiation 1055  
 Isolated limb infusions 157  
 Isotretinoin 630  
 Isotypes 735  
 Italy 379  
  
 JNK 303  
  
 Kallikrein 220  
 Kaposi's sarcoma 379, 1298  
 Kaposi's sarcoma herpesvirus 1298  
 Keratin 14 422  
 Keratinocytes 630  
 Ki-67 1106, 1781  
 Kidney neoplasms 984  
 Ki-ras 692  
 Kirsten ras mutations 692  
 KLK10 220  
 Knockout mouse 431  
  
 Laminin-1 1387  
 Laminin-5 383  
 Langerhans cells 1944  
 Laryngeal neoplasms 678  
 Laser capture microdissection 235  
 Letters to the Editors 137, 139, 140, 780, 781, 1418, 1606, 1607  
 Leucaphereses 1713  
 Leucovorin 798  
 Leukaemia 337  
 Leuprolide 333  
 Li-Fraumeni syndrome 293  
 Li-Fraumeni-like syndrome 209  
 LINE-1 1887  
 Lipid-mobilizing factor 758  
 Lipolysis 758  
 Liposomal doxorubicin 1850  
 Liver 1540  
 Liver metastases 504, 612  
 Liver microcirculation 431  
 Lombardia 379  
 Losartan 1396  
 Loss of heterozygosity 531, 1201, 1351, 1510, 1894  
 Loss of heterozygosity, *1p36* 204  
 Low-incidence areas 721  
 67LR 1387  
 Lugol 1006  
 Lung cancer 235, 255, 1326  
 Lung neoplasms 678  
 Lung tumours 1193  
 Luteinizing-hormone releasing hormone analogues 333  
 LY231514 649  
 Lycobetaine 1585  
 Lymph node metastases 93, 255, 1032  
 Lymphatic mapping 791  
 Lymphocytes 1731  
 Lymphocytic thyroiditis 1831  
 Lymphoma 463, 930, 1462  
 Lymphopenia 816  
 Lymphoscintigraphy 791  
  
 Macrophages 285  
*MAGE* 713  
*MAGE-A3* 1340  
 Magnetic resonance imaging 1655  
  
 Maintenance 29  
 Major histocompatibility complex-II 1193  
 Malignancy 1611  
 Malignant cell growth 618  
 Malignant melanomas 1871  
 Malignant mesothelioma 600, 863  
 Mammary carcinoma 546  
 Mammary glands 1522  
 Mammographies 225  
 Management 808  
 Mantova 379  
 Mapping 1510  
 Marimastat 1865  
 Mastectomy 668, 1952  
 Material deprivation 350  
 Matrigel 590  
 Matrix metalloproteinases 1865  
 Matrix metalloproteinase-1 1600  
 Matrix metalloproteinase-2 1706  
 Matrix metalloproteinase-9 1706  
 Maturation 1944  
*MBD2* 1168  
 MCF-7ras 917  
 MDA-MB-231 1978  
 MDM2 721, 1746  
 MDR 1987  
 MDR-1 1175  
*mdr-1* 1746  
 Meat 357  
*MeCP2* 1168  
 Mediterranean populations 1304  
 Medroxyprogesterone acetate 1  
 Medullary thyroid carcinoma 1546  
 Medulloblastoma 705, 1801  
 Melanomas 107, 157, 527, 741, 803, 1304, 1467, 1738  
 Melanoma, familial 836  
 Melanoma, human 1944  
 Melanoma thickness 1304  
 Melphalan 157  
 Men 641  
 Menopause 346  
 Meta-analysis 984, 991, 1700  
 Metabolism 630  
 Metalloproteinases 55, 122  
 Metastases 78, 285, 608, 1014, 1937  
 Metastatic germ cell tumours 823  
 Metastatic lesions 313  
 Metastatic non-small-cell lung cancer 1452  
 Methodology 1655  
 Methylation 199  
 Methylation-specific polymerase chain reaction 69  
 MHC alleles 1527  
 Microdialysis 157  
 Micrometastases 490, 1340  
  
 Microsatellite instability 568, 1037, 1064, 1147, 1486  
 Microsimulation models 1280  
 Migration 1387  
 Minisatellite 1486  
 Mismatch repairs 568  
 Mitochondria 1801  
 Mitogen-activated protein kinase 303, 1175, 1403  
 Mitomycin C 1137  
*MN/CA9* 563  
 Molecular and cellular mechanisms 1233  
 Molecular diagnostics 1546  
 Molecular profiles 538  
 Molecular-based diagnosis 102  
 Monoclonal antibodies 875, 1193, 1787, 1964  
 Monofunctional ZD2767 analogues 764  
 Monozygotic twins 493  
 Morbidity 325  
 Morphology 1535, 1978  
 Mortality 803, 1664  
 Mouse 930  
 MRP1 1564  
 MSH3 568  
 MSH6 568  
 Mucositis 1964  
 Multicell tumour spheroids 727  
 Multidrug resistance 1998  
 Multiple myeloma 1387  
 Multitargeted antifolate 649  
 Multivariate analysis 509  
 Muscle proteolysis 297  
 Mutational analysis 845  
 Mutations 199, 1383  
 MVR-PCR 1486  
*MYC* 705  
*MYCN* 531  
 Myeloma 325  
 Myoepithelial 422  
  
 NADH oxidase 1400  
 Neoplasms 261, 1700  
 Neuraminic acid 285  
 Neuritic differentiation 1564  
 Neuroblastomas 182, 493, 531, 1564, 2004  
 Neurotoxicity 1219  
 Neutrophils 463  
 Newborns 1295  
 Nipple aspirate fluid 1952  
 Node-negative primary breast cancer 795  
 Non-astrocytic tumours 204  
 Non-Hodgkin's lymphoma 1298, 1425, 1900  
 Non-melanoma skin cancer 683  
 Non-platinum-based regimen 1452  
 Non-seminomatous germ cell tumours 608  
 Non-small-cell lung cancer 9, 14, 129, 881, 939, 1113, 1247, 1456, 1706  
 Normal cytology 398

- Normal epithelial cell-specific 1 genes 220  
 Norway 959  
 Nottingham prognostic index 795  
 NQ01 1137  
 Nucleolus 1219  
 Nude rat 2004  
 Nurse-led clinics 1853  
 Nutrition 959
- Obesity 984  
 Odds ratio 991  
 Oesophageal cancer 341, 658, 661, 721, 1006, 1317, 1499, 1667, 1671, 1781  
 Oestradiol 317  
 Oestrogen 317, 1731  
 Oestrogen receptors 372, 546  
 Older women 1289  
 Oligodeoxynucleotides 1753  
 Oncogenes 697  
 Oncologists 1634  
 Oncology 1842  
 Ondansetron 1099  
 Oral administration 1472  
 Oral cancer 46  
 Oral cavity neoplasms 678  
 Oral squamous cell carcinoma 122  
 Oral topotecan 1124  
 Orthotopic xenografts 608  
 Osteoclasts 78  
 Osteosarcoma 1968  
 Outcome 325  
 Ovarian adenocarcinoma 1351  
 Ovarian cancer 190, 313, 687, 891, 944, 1064, 1124, 1175, 1359, 1540, 1592, 1627, 1753, 1824  
 Ovarian tumours 247  
 Overall survival 944  
 Oxaliplatin 1258
- P15* 1515  
*p16* gene 1383  
*p21* 1359  
*1p36* 204  
*p42/p44* kinases 1978  
*p53* 293, 1102, 1153, 1499, 1764, 1781  
*p53* 898, 902, 1878  
*p53* protein 1937  
*p53* tumour suppressor 1813  
*P63* 721  
*p73* 1499, 1551  
*p73* gene 204  
 Paclitaxel 141, 303, 902, 1472  
 Paediatric oncology 23  
 Pain 497  
 Pain measurements 497  
 Palliation 1265  
 Palliative care 816, 1478  
 Pancreatic cancer 612, 1865  
 Pancreatic cancer cells 752  
 Papillomavirus, human 398  
 Parathyroid-hormone-related protein 1722  
 Parotid glands 1055  
 Past use 674  
 Patients 1634  
 Patient participation 1273  
 Patient prognosis 313  
 Patterns of care 1251  
 Pemetrexed disodium 649  
 Pellet extracts 85  
 Pentoxifylline 1577  
 Pepsinogen C 228  
 Peptides 115  
 Performance status 1634  
 Peripheral benzodiazepine receptors 1771  
 Peripheral blood stem cells 1119  
 Peru 966  
 P-glycoprotein 1746, 1998  
 Pharmacogenetics 1425  
 Pharmacogenomics 107  
 Pharmacokinetics 1627  
 Phase I studies 1627  
 Phase II studies 9  
 Phenotypes 1368  
 Photodynamic therapies 279, 1794  
 Phthalocyanine 1787  
 Physical activity 962, 1311  
 PI-3K 303  
 Pigmentation 1304  
 Plasma membrane 1400  
 Plasminogen binding 909  
 Platelet-derived growth factor 1706  
 Platinum drugs 1219  
 Ploidy 14  
 Pluronic block copolymers 1987  
 Po Valley 379  
 Poisson regression 1335  
 Poliovirus vaccines 1295  
 Poly(ADP)ribose polymerase 1403  
 Polymer prodrugs 1070  
 Polymer-directed enzyme prodrug therapy 1070  
 Polymer-enzyme conjugates 1070  
 Polymerase chain reaction 1546  
 Polymorphisms 36, 171, 827, 1153, 1499, 1504  
 Polymyositis 41  
 Population health impacts 1280  
 Population studies 1347  
 Positron emission tomography 1640  
 Preclinical pharmacology 484  
 Prediction of response 1871  
 Predictive factors 1478  
 Pre-mRNA splicing 190  
 Present use 674  
 Prevention 428, 1280  
 Primary brain lymphomas 204  
 Primary breast cancer 74, 85, 1958  
 Profiles 1211  
 Progesterone receptors 372, 546  
 Prognosis 14, 85, 313, 367, 412, 552, 705, 808, 831, 863, 881, 1032, 1359, 1535, 1557, 1878  
 Prognostic factors 1646, 1671  
 Prognostic indicators 1958  
 Prognostic models 944  
 Prognostic values 1634  
 Progression 869  
 Proliferation 772  
 Proliferation status 727  
 Prophylactic treatment 1055  
 Prostaglandins 1023  
 Prostate androgen regulated transcript 1 393  
 Prostate cancer 115, 152, 393, 453, 557, 576, 641, 656, 991, 1504, 1722, 1928  
 Prostate spheroids 590  
 Prostate-specific antigens 656  
 Prostate-specific antigen mRNA bearing cells 557  
 Prostatic neoplasms 497  
 Protease-activated receptor-2 772  
 Proteins 357  
 Proteoglycans 1094  
 Proteolysis 74  
 Proteolysis-inducing factor 297  
 Protoporphyrin IX 727, 1572  
 Protracted venous infusion 1258  
 PR-transfection 1978  
 P-selectin 431  
 Psychological distress 1842
- Quality of life 497, 1265, 1478  
 Quantitative reverse transcriptase polymerase chain reaction 393
- RAC 3 1928  
 Radiation 1611, 1853  
 Radiosensitivity 1577, 2010, 2017  
 Radiotherapy 1233, 1671  
 Raf 1753  
 Ras oncogenes 235  
 RASCAL II Study 692  
 RCAS1 1922  
 Real-time quantitative reverse transcription-polymerase chain reaction 102  
 Receptors 171, 584, 1023  
 Receptor subtypes 266  
 Recombinant adeno-associated virus 1592  
 Recombinant adenovirus 1592  
 Record linkages 41  
 Rectal cancer 1437  
 Regional chemotherapy 157  
 Regional intra-arterial treatment 504  
 Regional variations in survival 637  
 Registries 497
- relA 1914  
 Renal cancer 1130  
 Renal cell carcinoma 563, 924, 953, 1372  
 Resistance 1746  
 Ret oncogene activation 1831  
 Retinoblastoma protein family 546  
 Retinoic acid 122, 2004  
 Retinoic acid receptors 453  
 Retinoic acid receptor antagonists 453  
 Retinoids 630  
 Reverse transcription-polymerase chainreaction 55, 405, 557, 1119, 1546, 1713  
 Rhabdomyosarcoma 831, 1746  
 Ribozymes 1185  
 Risk factors 428, 816, 972, 984, 1304, 1499, 1700  
 Rituximab 1619  
 RNA polymerase 190  
 Routine practices 1842  
 RT-PCR 1340  
 RU486 morphology 1978  
 S-1 939  
 Salvage chemotherapy 509, 798  
 Schistosomiasis 1037  
 SCID 608  
 Scintigraphy 1462  
 Screening 656, 1289, 1326, 1842  
 Second malignancies 997  
 Second-line chemotherapy 1456  
 Selective oestrogen receptor modulators 1838  
 Sensitisation 1987  
 Sentinel lymph nodes 791, 1340  
 Sequential chemotherapy 141  
 Serine protease 772  
 Serine/arginine-rich proteins 190  
 Serology 337  
 Serous carcinoma 247  
 Sexual habits 46  
 Sialic acid 285  
 Side-effects 1853  
 Sigmoidoscopy 972  
 Signal transduction 618  
 Skin tumours 1883  
 Small-cell lung cancer 808, 1444, 1713  
 Smoking 341  
 Sodium phenylacetate 917  
 Solid tumours 484  
 Soluble Fas ligands 1047  
 Somatostatin 266, 1462  
 Somatostatin receptors 266  
 Soya 618  
 Soyfood 372  
 Splicing factors 190  
 Sporadic renal cell carcinoma 1226  
 Squamous-cell cancer of the head and neck 1383

- Squamous-cell carcinoma  
   630, 658, 683, 721,  
   1006, 1883  
 Squamous cell carcinoma  
   of the oesophagus 412  
 Squamous papillomas 1794  
 SR family 190  
 SR-A1 190  
 Stages 787  
 Staging 863  
 Superantigens 129  
 Supportive care 1853  
 Suppression subtractive  
   hybridization 228, 1206  
 Surgery 1824  
 Surgery signals 490  
 Survival 367, 576, 637,  
   787, 808, 1251, 1492,  
   1850, 1900  
 Survival outcomes 1928  
 Survival rates 1671  
 Susceptibility 1504  
 SV40 1295  
 Synergism 917  
 Synovial sarcoma 405, 1535  
  
 Tamoxifen 317, 1106, 1130, 1280  
 Taxol 1175  
 tcf/lef transcription factors 98  
 Tegafur 939  
 Telomerase 752, 1006  
 Telomerase repressor  
   genes 1510  
 Telomere 898  
 Telomeric restriction  
   fragment 752  
 Tenascin-C 383  
  
 Testicular cancer 213, 220, 1624  
 Testicular germ cell  
   tumours 608  
 Thalidomide 953  
 Thymidine phosphorylase  
   surexpression 439  
 Thymidylate synthase 446,  
   827, 1937  
 Thyroglobulin 102  
 Thyroid cancer 102, 875, 1335  
 Thyroid carcinoma, familial  
   papillary 1831  
 Thyroid peroxidase 875  
 Time trends 1335  
 Tissue inhibitors of  
   metalloproteinases 55  
 Tissue-type plasminogen  
   activators 122  
 Tobacco 46  
 Tobacco chewing 661  
 Topoisomerase IIa 747  
 Topoisomerase IIb 747, 1585  
 Topoisomerase inhibitors 1077  
 Topotecan 1627  
 Toxicity 1850, 1865  
 TP53 721, 1359  
 Transfection 735  
 Transforming growth factor- $\beta$   
   687  
 Transforming growth factor- $\beta_1$   
   612  
 Transitional cell carcinoma,  
   human 1515  
 Transitional cell  
   carcinomas of the urinary  
   bladder 1894  
 Translocation 831  
  
 Treatment-related deaths 816  
 Trends 1664  
 TRF1 898  
 TRF2 898  
 Trypsin 772  
 TSC1 1226  
 TSC2 1226  
 Tubulin 735  
 Tumorigenesis 1185  
 Tumorigenicity 1914  
 Tumours 1655  
 Tumour angiogenesis 439  
 Tumour cell contamination 1713  
 Tumour dormancy 490  
 Tumour growth control 2010  
 Tumour incidence 674  
 Tumour markers 393, 552  
 Tumour perfusion 1577  
 Tumour spreading 600  
 Tumour suppressor genes 220,  
   697, 1887  
 Tumour targeting 1070  
 Tumour therapy 1540  
 Tumour-infiltrating lymphocytes  
   1722, 1871  
 Tumour-rejection antigens 713  
 Tumoural markers 1883  
 Tyrosinase 1738  
  
 Ubiquitin-proteasome  
   proteolysis 297  
 Ultraviolet radiation 1504  
 Ungeremine 1585  
 uPARs 85, 924  
 Uracil misincorporation 446  
 Urokinase 909  
 Urokinase-type  
   plasminogen activators 85, 924  
 Urologic neoplasms 977  
 Uterus 1023  
  
 V126D 527  
 Vaccines 1527, 1738  
 Vascular endothelial growth  
   factor 273, 313, 576,  
   584, 612, 795, 1706  
 Vascular endothelial growth  
   factor receptors 255  
 Vascular endothelial growth  
   factor-C 93, 255  
 Vascular endothelial growth  
   factor-dependent  
   proliferation 2010  
 Vascular endothelium 266  
 Vasculature 1968  
 Vinblastine 1998  
 Vinorelbine 1403  
 Vitamin-A 977, 2004  
 Vitamin-C 977  
 Vitamin-D 171  
 Vitamin-E 977  
 VM mouse 285  
 V $\alpha$ 24+NKT-cells 741  
 Vulval cancer 1551  
  
 Western blotting 1102  
 Wilms' tumour 1557  
  
 X-irradiation 752  
  
 ZD2767 764  
 ZD9331 446